In today’s health landscape, many countries are facing struggles with the levels of overweight people, obesity, and diabetes. This has been an ongoing concern in the United States, where lifestyles, diets, and socioeconomic factors fuel these health issues.
Going on vacation can be exciting. However, ensuring you are fully prepared for your much-anticipated trip abroad is important, especially if you plan on traveling with prescribed medications.
Though it may seem sensible to pack your prescription with you, you may just end up on the wrong side of the law when you reach your destination.
Around 21 million Americans have at least one addiction, ranging from smoking and excessive drinking to vaping and drugs. Even some prescription drugs can cause addictions if misused. These addictions are responsible for thousands of deaths every year, and only around 10% of people receive the treatment they need.
Have you ever wondered how much a hospital stay in New York might set you back compared to Texas or how much you might be expected to pay for an emergency room visit in California compared to Florida?
Medical tourism has increased over the last few years. From a market perspective, the revenue of medical tourism will be around $31.9 billion in 2023, a figure that is expected to grow at a compound annual growth rate of 14% over the next four years.
Insulin pumps are computerized devices that are about the size of a small smartphone. They are an insulin delivery system that is pre-programmed to help improve glucose control automatically.
Fiasp, a fast-acting insulin aspart injection, is a trademark of Novo Nordisk A/S. It is available in a multi-dose vial, a FlexTouch pen, a PenFill cartridge and device, and a PumpCart cartridge for use in compatible insulin pumps.
Farxiga (dapagliflozin) is an oral diabetes medication manufactured by AstraZeneca that is also FDA-approved to help treat heart failure and chronic kidney disease (CKD). It belongs to the drug class called sodium-glucose co-transporter 2 (SGLT-2) inhibitors.
Osteoporosis is a bone disease that weakens your bones and increases your risk of fractures. According to the National Osteoporosis Foundation, around 10 million people in the United States have osteoporosis.
Vemlidy is an oral antiviral drug manufactured by Gilead Sciences, Inc. It was approved by the U.S. Food and Drug Administration (FDA) in 2015 for the treatment of chronic hepatitis B virus (HBV) in adults and children aged 12 years and older.
